stamulumab

Stamulumab (MYO-029) is a recombinant human monoclonal IgG1λ antibody developed as an experimental therapy for muscle-wasting diseases, primarily various forms of muscular dystrophy. It functions by binding to and neutralizing myostatin (growth/differentiation factor 8, GDF-8), a protein that inhibits skeletal muscle growth. By preventing myostatin from interacting with its endogenous high-affinity receptor ActRIIB, stamulumab promotes muscle fiber hypertrophy. The drug was developed by Wyeth Pharmaceuticals and has undergone Phase 1 and Phase 2 clinical trials in patients with different types of muscular dystrophy, including Duchenne, Becker's, facioscapulohumeral, and limb-girdle muscular dystrophies[2][3][5][7].

Other names

stamulumab